MFN. IRA. European HTA reform — every pricing move abroad now flows back to your US pricing and launch strategy. 150+ manufacturers trust JSC to navigate what's next.
Our team replies within 24 hours. No commitment.
CMS now structurally links what you charge abroad to what you receive in the US. Every reference-country price has direct US revenue consequences.
Mandatory international benchmarking for high-cost, single-source drugs across 17 USP therapeutic categories. Net prices indexed to 19 OECD reference countries.
Extends international benchmarking to retail and specialty pharmacy drugs across 6 therapeutic categories.
Voluntary rebates aligning Medicaid net prices with the second-lowest across 8 reference countries (United Kingdom, France, Germany, Italy, Canada, Japan, Denmark and Switzerland), GDP-adjusted.
We partner with pharma, biotech, medtech and digital health companies to protect pricing, secure reimbursement and de-risk launches across the US and European markets.
We model your pricing corridor across 19 MFN reference countries and stress-test launch sequencing - protecting US value while securing European access.
Reimbursement and HTA submissions across the US and EU — AMCP-format dossiers and ICER value assessments stateside, and country-specific dossiers for G-BA (DE), HAS (FR), NICE (UK), AIFA (IT) and AEMPS (ES) as well as JCA dossiers for EU.
We support engagement with U.S. payers, PBMs, integrated delivery networks, Medicare stakeholders and European HTA agencies. Our approach spans negotiation preparation, access strategy, launch readiness and post-launch price defense.
JSC supports US manufacturers across the American, European and international markets, with on-the-ground expertise in every major MFN reference country.
"Their expertise and ease of communication have greatly enriched our projects. The team has deep knowledge of EU HTA processes, making them an invaluable asset for navigating complex reimbursement environments."
"A company and team with real, hands-on experience developing market access strategies in pharma. Justin Stindt Consulting consistently delivers high-quality work that stands up in the real, complex world of market access."
"JSC organized a series of advisory boards for us which were very insightful and informed our evidence generation and Market Access strategy."
Our senior team replies within 24 hours. No commitment. Whether you are two years out from launch or already in-market, we will help you pressure-test your global pricing and market access strategy under the new MFN reality.
Response within 24h — No commitment.